NCT01375608View on ClinicalTrials.gov

Decitabine for High-Risk Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

February 29, 2016

Conditions
NeutropeniaSickle Cell Disease
Interventions
DRUG

Decitabine

0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT01375608 - Decitabine for High-Risk Sickle Cell Disease | Biotech Hunter | Biotech Hunter